IP Library › Granted Patent US 12,492,410
Granted Patent B2
US 12,492,410 · App. 17/823,003 · Granted Dec 9, 2025

Engineered cytolytic immunecell

Inventors: Shaun Cordoba (London, GB); Shimobi Onuoha (London, GB); Alexander Kinna (London, GB); Simon Thomas (London, GB); Ram Jha (London, GB); Martin Pulé (London, GB)
Assignee: AUTOLUS LIMITED
C12N15/85A61K40/11A61K40/31C07K14/7051C12N5/0636G01N33/5011G01N33/5014A61K2239/31A61K2239/48C07K2317/569C12N2510/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,492,410
App. No.
17/823,003
Granted
Dec 9, 2025
Kind
B2
Abstract

The present invention relates to engineered a cytolytic immune cell comprising: i) a releasable protein which comprises a polypeptide of interest (POI) and a first interaction domain; and ii) a retention protein which is retained within an intracellular compartment of the cell and comprises a second interaction domain which binds to the first protein interaction domain, wherein binding between the first protein interaction domain and second protein interaction domain is disrupted by the presence of an agent, such that in the absence of the agent, the first protein interaction domain and second protein interaction domain bind and result in retention of the POI within an intracellular compartment; whereas in the presence of the agent, the first protein interaction domain and second protein interaction do not bind and the POI is released from the intracellular compartment and expressed at the cell surface or secreted by the cell.

Claims (6)

1 . A minocycline-binding domain antibody of SEQ ID NO: 8, 9, 10, 11, 12 or 13.

2 . A nucleic acid encoding a domain antibody according to claim 1 .

3 . A vector comprising a nucleic acid according to claim 2 .

4 . A host cell comprising a vector according to claim 3 .

5 . The cell according to claim 4 , wherein the cell is a T cell or an NK cell.

6 . A pharmaceutical composition comprising a plurality of cells according to claim 5 .

Assignments (2)
PATENT SECURITY AGREEMENT Recorded Jul 30, 2026
From: AUTOLUS LIMITED
To: PERCEPTIVE CREDIT HOLDINGS V, LP, AS ADMINISTRATIVE AGENT
Reel/Frame 076084/0283 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Oct 5, 2022
From: PULÉ, MARTIN; CORDOBA, SHAUN; ONUOHA, SHIMOBI; KINNA, ALEX; THOMAS, SIMON; JHA, RAM
To: AUTOLUS LIMITED
Reel/Frame 061322/0780 →
Priority Claims (1)
GB 1805918 · Apr 10, 2018 · national
Continuity (2)
Continuation 17046243
Related Publication 20230090553A1 · Mar 23, 2023
References Cited (44)
US 7052906B1 · Lawson et al. · 2006 [cited by applicant]
US 10654927B2 · Pulé · 2020 [cited by examiner]
US 11466070B2 · Pulé et al. · 2022 [cited by applicant]
US 12187769B2 · Pulé · 2025 [cited by examiner]
US 20170081411A1 · Engels et al. · 2017 [cited by applicant]
US 20180086831A1 · Pule et al. · 2018 [cited by applicant]
US 20190330299A1 · Pulé et al. · 2019 [cited by applicant]
US 20200188434A1 · Cordoba et al. · 2020 [cited by applicant]
US 20200338124A1 · Cordoba et al. · 2020 [cited by applicant]
US 20240091357A1 · Pulé et al. · 2024 [cited by applicant]
CN 107207621A · 2017 [cited by applicant]
JP 2002535959A · 2002 [cited by applicant]
JP 2017526361A · 2017 [cited by applicant]
WO WO0023602A2 · 2000 [cited by applicant]
WO WO201617440A1 · 2016 [cited by applicant]
WO WO2016030691A1 · 2016 [cited by examiner]
WO WO2016135470A1 · 2016 [cited by applicant]
WO WO2016174405A1 · 2016 [cited by applicant]
WO WO2016174406A1 · 2016 [cited by applicant]
WO WO2016174407A1 · 2016 [cited by applicant]
WO WO2016174408A1 · 2016 [cited by applicant]
WO WO2016174409A1 · 2016 [cited by applicant]
WO WO2017137758A1 · 2017 [cited by applicant]
WO WO2018211244A1 · 2018 [cited by applicant]
WO WO2018211245A1 · 2018 [cited by applicant]
WO WO2021069915 · 2021 [cited by applicant]
Gao, et al., J Env Sci and Health, Part B, 2013, 48, 92-100 (Year: 2013). [cited by examiner]
U.S. Appl. No. 17/767,806, filed Apr. 8, 2022. [cited by applicant]
Chmielewski et al., “CAR T Cells Transform to Trucks: Chimeric Antigen Receptor-Redirected T Cells Engineered to Deliver Inducible IL-12 Modulate the Tumour Stroma to Combat Cancer,” Cancer Immunology Immunotherapy, 61:… [cited by applicant]
Chmielewski et al., “IL-12 Release by Engineered T Cells Expressing Chimeric Antigen Receptors can Effectively Muster an Antigen-Independent Macrophage Response on Tumor Cells That Have Shut Down Tumor Antigen Expressio… [cited by applicant]
Chmielewski et al., “Of CARs and Trucks: Chimeric Antigen Receptor (CAR) T Cells Engineered with an Inducible Cytokine to Modulate the Tumor Stroma,” Immunological Reviews, 257:83-90 (2014). [cited by applicant]
Donnelly et al., “The cleavage activities of foot-and-mouth disease virus 2A site-directed mutants and naturally occurring 2A-like sequences,” J. Gen. Virol. 82:1027-1041 (2001). [cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/GB2019/051031 dated Sep. 19, 2019. [cited by applicant]
Kuo et al., “Structural insights into TDP-43 in nucleic-acid binding and domain interactions,” Nucleic Acids Res. ; 37(6):1778-88 (2009). [cited by applicant]
Rivera et al., “Regulation of Protein Secretion through Controlled Aggregation in the Endoplasmic Reticulum,” Science, 287:826-830 (2000). [cited by applicant]
White et al., “Protein-protein interactions as targets for small-molecular therapeutics in cancer,” Expert Rev. Mol. Med. 10:e8, 14 pages (2008). [cited by applicant]
Casset F., et al., “A Peptide Mimetic of an anti-CD4 Monoclonal Antibody by Rational Design”, Biochemical and Biophysical Research Communications, vol. 307, 2003, pp. 198-205. [cited by applicant]
Edwards B.M., et al., “The Remarkable Flexibility of the Human Antibody Repertoire; Isolation of Over One Thousand Different Antibodies to a Single Protein, BlyS,” Journal of Molecular Biology, 2003, vol. 334, pp. 103-1… [cited by applicant]
Goel M., et al., “Plasticity within the Antigen-Combining Site May Manifest as Molecular Mimicry in the Humoral Immune Response,” Journal of Immunology, 2004, vol. 173, pp. 7358-7367. [cited by applicant]
Luckner S.R., et al., “How an Agonist Peptide Mimics the Antibiotic Tetracycline to Induce Tet-Repressor,” Journal of Molecular Biology, Academic Press, UK, doi:10.1016/J.JMB.2007.02.030, ISSN 0022-2836, XP022020037, 20… [cited by applicant]
MacCallum R.M., et al., “Antibody-antigen Interactions: Contact Analysis and Binding Site Topography”, Journal of Molecular Biology, vol. 262, 1996, pp. 732-745. [cited by applicant]
Panka D.J., et al., “Variable Region Framework Differences Result in Decreased or Increased Affinity of Variant Anti-Digoxin Antibodies”, Proceedings of the National Academy of Sciences USA, vol. 85, May 1988, pp. 3080-… [cited by applicant]
Poosarla V.G., et al., “Computational De Novo Design of Antibodies Binding to a Peptide With High Affinity,” Biotechnology and Bioengineering, Jun. 2017, vol. 114 (6), pp. 1331-1342. [cited by applicant]
Rudikoff S., et al., “Single Amino Acid Substitution Altering Antigen-Binding Specificity”, Immunology, Proceedings of the National Academy of Sciences, 1982, vol. 79, pp. 1979-1983. [cited by applicant]